← Harvard Apparatus Regenerative Technology, Inc. (HRGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Surgical & Medical Instruments & Apparatus · market cap $40M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
7
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Testosterone | Phase 3 | Hip Fracture |
| LACTIN-V | Phase 2 | Bacterial Vaginosis |
| Folinic Acid | Phase 2 | Autism Spectrum Disorder |
| Theophylline | Phase 2 | Pseudohypoparathyroidism |
| glucagon | Phase 2 | Post-bariatric Hypoglycemia |
| Ezogabine | Phase 2 | Amyotrophic Lateral Sclerosis |
| alcohol | Phase 2 | Type 2 Diabetes |
Price & technical context
3-month
+90.4%
6-month
+17.9%
12-month
+7.6%
52-wk range
$1.00–$2.35
vs 50-day MA
+22.9%
vs 200-day MA
+26.9%
Realized vol
90.1%
Max drawdown
-82.4%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HRGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.